Clinical Trial Update: Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating endocrine therapy plus OSI-906, with or without erlotinib, for hormone-sensitive metastatic breast cancer was terminated and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• OSI-906 (OSI-906)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Hormone-sensitive Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-09-11